Form 4: Inhibrx Inc. Reports Changes in Beneficial Ownership Following Stock Distribution
SEC Form 4 Filing
Inhibrx, Inc. reports a distribution of Inhibrx Biosciences, Inc. common stock to its shareholders, resulting in changes in beneficial ownership.
Summary
- On January 8, 2024, Inhibrx, Inc. (RemainCo) acquired 100 shares of Inhibrx Biosciences, Inc.
- On May 29, 2024, a stock split resulted in RemainCo owning 14,474,066 shares of Inhibrx Biosciences, Inc.
- On May 29, 2024, RemainCo distributed approximately 92% of the Inhibrx Biosciences, Inc. common stock to its shareholders of record as of May 17, 2024.
- Following the distribution, Inhibrx, Inc. directly owns 1,157,926 shares of Inhibrx Biosciences, Inc.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing related to a corporate action. The sentiment is neutral as it primarily reports factual information about the stock distribution.
Industry Context
This filing reflects a corporate action, specifically a distribution of shares, which is a common strategy for companies to unlock value or streamline operations. The distribution allows Inhibrx, Inc. shareholders to directly own shares of Inhibrx Biosciences, Inc.
Stakeholder Impact
- Shareholders of Inhibrx, Inc. received shares of Inhibrx Biosciences, Inc.
Key Dates
| Date | Description |
|---|---|
| 2024-01-08 | Inhibrx, Inc. acquired 100 shares of Inhibrx Biosciences, Inc. |
| 2024-05-17 | Record date for shareholders eligible for the stock distribution. |
| 2024-05-29 | Date of the stock split and distribution of Inhibrx Biosciences, Inc. common stock. |
| 2024-05-31 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.